Valuation: MedinCell

Market Cap 781M 907M 740M 671M 1.26B 86.65B 1.26B 8.79B 3.38B 44.08B 3.41B 3.33B 139B P/E 2027 *
363x
P/E 2028 * 45.7x
Enterprise Value 767M 890M 726M 658M 1.23B 85B 1.24B 8.62B 3.32B 43.24B 3.34B 3.27B 137B EV / Sales 2027 *
17.4x
EV / Sales 2028 * 12.7x
Free-Float
66.06%
Yield 2027 *
-
Yield 2028 * -
Manager TitleAgeSince
Chief Executive Officer 62 08/01/2003
Director of Finance/CFO 52 31/08/2023
Chief Tech/Sci/R&D Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 62 08/01/2003
Chairman - 12/03/2024
Director/Board Member - 24/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 907M
-0.65%-2.93%+47.70%+86.30% 994B
-0.29%-3.51%+49.15%+61.95% 640B
+0.83%+0.26%+17.76%+70.10% 454B
+3.81%+0.88%+36.98%+37.43% 337B
+2.23%-8.66%+17.35%+25.62% 261B
+2.38%-0.60%+4.87%+10.69% 246B
-1.34%-13.70%+36.53%+46.70% 204B
+1.56%-6.10%-20.95%-58.90% 190B
-0.75%-4.82%+25.46%+85.90% 178B
Average +0.79%-5.76%+23.87%+40.64% 389.42B
Weighted average by Cap. +0.55%-4.42%+32.29%+55.04%

Financials

2027 *2028 *
Net sales 44.14M 51.23M 41.8M 37.89M 71.07M 4.89B 71.43M 496M 191M 2.49B 192M 188M 7.87B 58.92M 68.39M 55.79M 50.57M 94.87M 6.53B 95.35M 663M 255M 3.32B 257M 251M 10.5B
Net income 667K 774K 631K 572K 1.07M 73.92M 1.08M 7.5M 2.88M 37.61M 2.91M 2.84M 119M 13.33M 15.47M 12.62M 11.44M 21.46M 1.48B 21.57M 150M 57.63M 752M 58.09M 56.81M 2.38B
Net Debt -14.87M -17.25M -14.08M -12.76M -23.94M -1.65B -24.06M -167M -64.29M -839M -64.8M -63.38M -2.65B -30.53M -35.44M -28.91M -26.2M -49.16M -3.39B -49.41M -343M -132M -1.72B -133M -130M -5.44B
Logo MedinCell
MedinCell S.A. is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2026, the company had a portfolio of a product in phase III clinical development and 3 products in preclinical development.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.76EUR
Average target price
34.51EUR
Spread / Average Target
+58.60%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!